Author Question: A health care provider reads in the medical record that a patient is receiving valacyclovir ... (Read 89 times)

maychende

  • Hero Member
  • *****
  • Posts: 556
A health care provider reads in the medical record that a patient is receiving valacyclovir (Val-trex). Review the following viral infections, and select the one that the health care provider ex-pects to see in the patient's history.
 
  a. Cytomegalovirus (CMV) retinitis
  b. Human immunodeficiency virus (HIV)
  c. Respiratory syncytial virus (RSV)
  d. Herpes genitalis

Question 2

Which of the following laboratory tests should be monitored at least weekly in a patient receiving ganciclovir (Cytovene)?
 
  a. Serum albumin and total protein
  b. Serum electrolytes and blood glucose
  c. Neutrophil and platelet counts
  d. Amylase and lipase



fatboyy09

  • Sr. Member
  • ****
  • Posts: 358
Answer to Question 1

ANS: D
Valacyclovir is a prodrug form of acyclovir that is indicated in the oral treatment of herpes zoster and recurrent genital herpes in immunocompetent adults.

Answer to Question 2

ANS: C
Ganciclovir can cause a potentially fatal neutropenia, which is the most common dose-limiting effect of the drug. It can also cause thrombocytopenia, resulting in the need to monitor neutro-phil and platelet counts at least weekly during therapy.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question


 

Did you know?

Cutaneous mucormycosis is a rare fungal infection that has been fatal in at least 29% of cases, and in as many as 83% of cases, depending on the patient's health prior to infection. It has occurred often after natural disasters such as tornados, and early treatment is essential.

Did you know?

Acute bronchitis is an inflammation of the breathing tubes (bronchi), which causes increased mucus production and other changes. It is usually caused by bacteria or viruses, can be serious in people who have pulmonary or cardiac diseases, and can lead to pneumonia.

Did you know?

Calcitonin is a naturally occurring hormone. In women who are at least 5 years beyond menopause, it slows bone loss and increases spinal bone density.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

Did you know?

More than 4.4billion prescriptions were dispensed within the United States in 2016.

For a complete list of videos, visit our video library